New share issue in Bluefish Pharmaceuticals AB
• New share issue aiming to raise approximately SEK 25 million
• Share price to be SEK 6.50
• New number of shares to be issued will be 3 850 000
• Subscription period from 16th of June until and including 24th of June 2010
• The share issue is guaranteed to 100% by Färna Invest AB
The Board of Directors of Bluefish Pharmaceuticals AB (“Bluefish”) has resolved to issue new shares in Bluefish with the intention of raising approximately SEK 25 million. The funds will be used to secure continue investments in the product portfolio as well as supporting the increased need for working capital.
The share issue will increase the share capital with a maximum of SEK 770 000 through the issue of not more than 3 850 000 new B shares, if fully subscribed the total number of shares will be 33 398 684.The price to be SEK 6.50 per share and the subscription period will be from 16th of June until and including 24th of June 2010.
The share issue is guaranteed to 100% by Färna Invest AB, one of the major shareholders in Bluefish, in addition has Karl Karlsson President & CEO and founder of Bluefish committed to invest SEK 3,5 million in the share issue.
Time schedule for the share issue:
- 16th to 24th of June, Subscription period
- 22nd of June at 11.30, Investor Q&A session at Bluefish
- 28th of June, Settlement Notes sent
- Payment approx. 3 days
For more information contact,
Karl Karlsson, President & CEO Bluefish Pharmaceuticals
Tel. +46 8 519 11 600
Email: karl.karlsson@bluefishpharma.com
Åsa Axelsson, Deputy CFO Bluefish Pharmaceuticals
Tel. +46 8 519 11 600
Email: asa.axelsson@bluefishpharma.com
About Bluefish Pharmaceuticals
Bluefish Pharmaceuticals offers high quality, cost effective generic pharmaceuticals of great medical value to patients. The company was founded in 2005 with the ambition to create a pan-European pharmaceutical company with focus on product development, registration and marketing.
The company's product portfolio consists of 33 products, whereof 26 are approved in at least one European country, and another 7 are under registration. Bluefish has offices in Sweden, India, Austria, Germany, Italy, Hungary, Poland and the Netherlands.
www.bluefishpharma.com